News >

European Commission Approves Maintenance Rucaparib in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 24, 2019

Patrick J. Mahaffy

Patrick J. Mahaffy

The European Commission has approved an expanded indication for single-agent rucaparib (Rubraca) as a maintenance therapy in adult patients with platinum-sensitive, relapsed, high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA status.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication